Differential effects of recombinant human growth hormone on glomerular filtration rate and renal plasma flow in chronic renal failure.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

The researchers have measured clearance of inulin and para-aminohippuric acid in 18 children with chronic renal failure (CRF) during their 1st year of rhGH treatment to look at the immediate (first 3 h), short-term (1 week) and long-term (1 year) effects of treatment.

On day 1 mean (range) age was 9.1 (4.9-13.9) years, GFR 19 (9-58) and ERPF 77 (34-271) ml/min per 1.73 m2.

Who Took Part

The abstract describes 18 children taking part.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

What Was Measured

The researchers have measured clearance of inulin and para-aminohippuric acid in 18 children with chronic renal failure (CRF) during their 1st year of rhGH treatment to look at the immediate (first 3 h), short-term (1 week) and long-term (1 year) effects of treatment.

Topics PubMed links to this paper include Blood Pressure, Body Height, Creatinine, Glomerular Filtration Rate, Growth Disorders, Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.